Cibus, Inc. (CBUS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-10

Key Insights

Cibus, Inc. has appointed Thomas Urban, an experienced agricultural industry executive, to its Board of Directors. This brings valuable expertise and industry connections to the company.
The compensation package for the new director includes a cash retainer and equity grants, aligning his interests with those of shareholders.
There appear to be no concerning related-party transactions or other conflicts of interest associated with the new director appointment.

Want the newest filings?

This analysis covers the filing from 2026-04-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-27

Cibus, Inc. announced a $13.5 million public offering of its Class A common stock, with an additional $2.5 million option for the underwriter.
The offering is expected to close on March 27, 2026, subject to customary closing conditions.
The company plans to use the net proceeds from the offering for general corporate purposes, including funding future growth initiatives.

Filed: 2026-03-17

Cibus, Inc. reported its Q4 2025 and full year 2025 financial results, providing an update on the company's business operations.
The company's financial performance and business update suggest continued growth and progress, which could be positive for investors.
However, the filing does not provide detailed financial information or guidance, so further analysis of the full financial statements and management's commentary would be needed to fully assess the company's performance and outlook.

Filed: 2026-01-30

Cibus is raising approximately $17.8 million in an underwritten public offering, with an option to raise up to $20.5 million if the over-allotment option is exercised. This funding will likely support the company's ongoing operations and growth initiatives.
Members of Cibus' board of directors are personally investing $1.5 million in the offering, indicating their confidence in the company's prospects.
The offering is being made pursuant to Cibus' existing shelf registration statement, providing flexibility for future capital raises if needed.

Filed: 2026-01-28

Cibus is focusing its business on developing herbicide tolerance traits for rice, which it believes can generate over $200 million in annual royalties upon full commercialization across key global markets.
Cibus is streamlining its operations to reduce annual net cash usage to $30 million or less in 2026, which could improve the company's financial stability.
Cibus is continuing to advance its sustainable ingredients programs, including a biofragrance products program with estimated annual revenue potential of $20-40 million over the long term.

Other reports for Cibus, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.